| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $4,125,056 ) |
| | 2025 | 2025 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS143578 | Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC | 001 | 1 | NIH | 9/18/2025 | $0 |
| | 2025 | 2025 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44AI172670 | Protein depleting pre-existing antibodies for viral gene therapy | 001 | 3 | NIH | 7/25/2025 | $969,817 |
| | 2025 | 2025 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44NS135667 | Development of gene therapy product for treating MPS IIIB | 002 | 2 | NIH | 9/3/2025 | $1,305,826 |
| | 2025 | 2025 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44NS143501 | Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I | 000 | 1 | NIH | 9/16/2025 | $722,587 |
| | 2025 | 2025 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44NS143501 | Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I | 000 | 1 | NIH | 9/16/2025 | $776,917 |
| | 2025 | 2025 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS143578 | Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC | 000 | 1 | NIH | 7/8/2025 | $349,909 |
| | 2025 | 2024 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44NS135667 | Development of gene therapy product for treating MPS IIIB | 001 | 1 | NIH | 2/13/2025 | $0 |
| | 2025 | 2024 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44NS135667 | Development of gene therapy product for treating MPS IIIB | 000 | 1 | NIH | 10/28/2024 | $0 |
| | 2025 | 2023 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44AI172670 | Protein depleting pre-existing antibodies for viral gene therapy | 000 | 1 | NIH | 3/25/2025 | $0 |
| | 2025 | 2023 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS127726 | Develop AAV9 gene replacement therapy for treating MPS I | 000 | 2 | NIH | 6/5/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,453,592 ) |
| | 2024 | 2024 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44AI172670 | Protein depleting pre-existing antibodies for viral gene therapy | 001 | 2 | NIH | 8/8/2024 | $1,000,000 |
| | 2024 | 2024 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44NS135667 | Development of gene therapy product for treating MPS IIIB | 000 | 1 | NIH | 8/30/2024 | $456,414 |
| | 2024 | 2023 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44AI172670 | Protein depleting pre-existing antibodies for viral gene therapy | 000 | 1 | NIH | 11/21/2023 | $0 |
| | 2024 | 2021 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS115232 | Development of gene therapy product for treating MPS IIIB | 000 | 2 | NIH | 1/5/2024 | -$2,822 |
|
| Issue Date FY: 2023 ( Subtotal = $630,302 ) |
| | 2023 | 2023 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R44AI172670 | Protein depleting pre-existing antibodies for viral gene therapy | 000 | 1 | NIH | 7/27/2023 | $306,500 |
| | 2023 | 2023 | NEUROGT INC | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS127726 | Develop AAV9 gene replacement therapy for treating MPS I | 000 | 2 | NIH | 8/16/2023 | $323,802 |
|
| Issue Date FY: 2022 ( Subtotal = $378,882 ) |
| | 2022 | 2022 | NEUROGT, INC. | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS127726 | Develop AAV9 gene replacement therapy for treating MPS I | 000 | 1 | NIH | 7/29/2022 | $378,882 |
| | 2022 | 2021 | NEUROGT, INC. | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS115232 | Development of gene therapy product for treating MPS IIIB | 000 | 2 | NIH | 5/2/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $284,425 ) |
| | 2021 | 2021 | NEUROGT, INC. | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS115232 | Development of gene therapy product for treating MPS IIIB | 000 | 2 | NIH | 3/30/2021 | $284,425 |
|
| Issue Date FY: 2020 ( Subtotal = $397,823 ) |
| | 2020 | 2020 | NEUROGT, INC. | 5 SILVERTON CT | DURHAM | NC | 27713-9400 | DURHAM | USA | R41NS115232 | Development of gene therapy product for treating MPS IIIB | 000 | 1 | NIH | 4/7/2020 | $397,823 |
|
|
